The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review

Nilasha Ghosh; Bridget Jivanelli; Nina Couette; Namrata Singh; Marie Kostine; Alexa Simon Meara; David F L Liew

doi:10.1016/j.rdc.2024.02.006

The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review

Rheum Dis Clin North Am. 2024 May;50(2):325-335. doi: 10.1016/j.rdc.2024.02.006. Epub 2024 Mar 12.

Authors

Nilasha Ghosh¹, Bridget Jivanelli², Nina Couette³, Namrata Singh⁴, Marie Kostine⁵, Alexa Simon Meara⁶, David F L Liew⁷

Affiliations

¹ Department of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. Electronic address: ghoshn@hss.edu.
² Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA.
³ Department of Rheumatology, Rheumatology Care Center, Genesis Healthcare System, 2525 Maple Avenue, Zanesville, OH 43701, USA.
⁴ Division of Rheumatology, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.
⁵ Department of Rheumatology, Bordeaux University Hospital, 311 Président Wilson Boulevard, Bordeaux 33200, France.
⁶ Division of Oncology, Department of Medicine, The Ohio State University Wexner Medical Center, 460 West 10th Avenue, Columbus, OH 43210, USA.
⁷ Department of Rheumatology, Austin Health; Department of Clinical Pharmacology and Therapeutics, Austin Health; Department of Medicine, University of Melbourne, Level 1, North Wing, 300 Waterdale Road, PO Box 5444, Heidelberg West, Victoria 3081, Australia.

PMID: 38670730
DOI: 10.1016/j.rdc.2024.02.006

Abstract

Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event that can occur as a result of receiving ICIs for cancer treatment. Thus far, ICI-IA has been described variably in the literature, in part due to varying presentations that evolve over time, as well as a lack of standardized definitions and classification. This scoping review aggregates various descriptions of ICI-IA, highlighting the most prominent attributes of ICI-IA from categories such as symptoms, signs, imaging, and laboratory findings as well as discussing potential mimic conditions.

Keywords: Cancer; Immune checkpoint inhibitors; Immune-related adverse events; Immunotoxicity; Inflammatory arthritis.

Publication types

Review

MeSH terms

Arthritis* / chemically induced
Arthritis* / drug therapy
Humans
Immune Checkpoint Inhibitors* / adverse effects
Neoplasms / drug therapy
Neoplasms / immunology

Substances

Immune Checkpoint Inhibitors